Can azelastine (intranasal antihistamine) and fluticasone propionate (intranasal corticosteroid) be used together to treat rhinosinusitis?

Azelastine + Fluticasone for Rhinosinusitis

For moderate-to-severe seasonal allergic rhinitis in patients ≥12 years, combination intranasal azelastine-fluticasone provides superior symptom control compared to either agent alone and should be considered as initial therapy, though this is a weak recommendation due to added cost and potential side effects. However, the evidence specifically addresses allergic rhinitis, not acute or chronic rhinosinusitis.

Key Clinical Context

The provided evidence focuses almost entirely on seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR), not rhinosinusitis. This is a critical distinction:

• Allergic rhinitis = IgE-mediated inflammation of nasal membranes
• Rhinosinusitis = inflammation of nasal passages AND paranasal sinuses (infectious or inflammatory)

Evidence for Allergic Rhinitis

The 2017 Joint Task Force guidelines 1 provide a weak recommendation for combination intranasal corticosteroid + intranasal antihistamine in moderate-to-severe SAR for patients ≥12 years. The evidence shows:

• Symptom reduction hierarchy: Fluticasone + azelastine (-5.31 to -5.7 TNSS reduction) > fluticasone alone (-3.84 to -5.1) > azelastine alone (-3.25 to -4.54) > placebo (-2.2 to -3.03) 1
• Greater than 40% relative improvement with combination therapy versus monotherapy 1
• Clinically meaningful differences in Total Nasal Symptom Score (TNSS), though quality of life improvements did not consistently exceed minimal clinically important difference 1

Why the Weak Recommendation?

The guideline panel graded this as weak (not strong) because 1:

• Concerns about potential bias in available studies
• Lack of studies addressing add-on therapy (most started with combination vs. monotherapy)
• Greater potential for adverse effects (dysgeusia 2.1-13.5%, somnolence 0.4-1.1%)
• Added cost of using two medications

Dosing Specifics

FDA-approved dosing for azelastine 2:

• Seasonal allergic rhinitis (≥5 years): 1-2 sprays per nostril twice daily
• Vasomotor rhinitis (≥12 years): 2 sprays per nostril twice daily

Combination therapy studied 1:

• Fluticasone propionate 200 mcg + azelastine 548 mcg as single spray, OR
• Fluticasone propionate + azelastine 1100 mcg daily using separate devices

Adverse Effects Profile

Common side effects 1, 2:

• Dysgeusia (bitter taste): Most common, 2.1-13.5%
• Epistaxis: Similar to or lower than placebo
• Somnolence: 0.4-1.1% (minimal)
• Headache, nasal irritation: Low incidence

Safety considerations:

• No significant systemic effects in adults
• No growth suppression in children at recommended doses
• Rare nasal septal perforation reported

Evidence for Actual Rhinosinusitis

Chronic Rhinosinusitis (CRS)

The 2020 European Position Paper on Rhinosinusitis 3 states:

• Intranasal corticosteroids are the mainstay for CRS symptoms
• Long-term adherence to intranasal corticosteroids is essential
• Mometasone furoate, fluticasone propionate, and fluticasone furoate preferred for safety (negligible bioavailability)
• No specific recommendation for adding intranasal antihistamines to corticosteroids for CRS

Emerging evidence 4: One recent study in Central Compartment Atopic Disease (a CRSwNP subtype) showed combined azelastine/fluticasone provided better postoperative control than fluticasone alone, with less polyp recurrence. However, this is a single study in a specific CRS subtype.

Acute Rhinosinusitis (ARS)

For acute post-viral rhinosinusitis 3:

• Intranasal corticosteroids may be recommended if symptom reduction is needed
• No evidence supporting intranasal corticosteroids for common cold
• No specific evidence for adding intranasal antihistamines

Recurrent acute rhinosinusitis 5: One retrospective study showed intranasal azelastine reduced episodes from 2.72 to 1.18 per year (56.6% reduction), but this requires prospective validation.

Clinical Algorithm

For Allergic Rhinitis (NOT Rhinosinusitis):

1. Mild symptoms: Start with intranasal corticosteroid alone (most effective monotherapy) 1

2. Moderate-to-severe symptoms (≥12 years):

   • First-line: Consider combination azelastine-fluticasone 1, 6
   • Provides 15-30 minute onset of action 7
   • Superior symptom control versus monotherapy 8, 9

3. Pediatric patients (6-12 years):

   • Evidence emerging but limited 7
   • Intranasal corticosteroid alone remains standard

4. If cost or tolerability concerns: Start with intranasal corticosteroid alone, add intranasal antihistamine if inadequate response

For Rhinosinusitis:

1. Chronic rhinosinusitis:

   • Intranasal corticosteroid alone (fluticasone propionate, mometasone furoate, or fluticasone furoate) 3
   • Consider adding azelastine only if significant allergic component or inadequate response to corticosteroid alone

2. Acute post-viral rhinosinusitis:

   • Intranasal corticosteroid if symptom reduction needed 3
   • No established role for intranasal antihistamines

3. Recurrent acute rhinosinusitis:

   • Insufficient evidence for combination therapy
   • Consider azelastine prophylaxis based on emerging data 5

Critical Pitfalls

• Don't confuse allergic rhinitis with rhinosinusitis - they require different management approaches
• Don't use combination therapy as universal first-line - the recommendation is weak, and monotherapy with intranasal corticosteroid is often sufficient and more cost-effective
• Don't expect immediate quality of life improvements - while symptom scores improve, QOL benefits may not reach minimal clinically important difference 1
• Don't forget to counsel about bitter taste - dysgeusia is the most common side effect and may affect adherence 1
• Don't use for common cold - no evidence of benefit 3